Opportunity Information: Apply for PAR 14 086
Apply for PAR 14 086
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.396 Cancer Biology Research.
- This funding opportunity was created on Feb 4, 2014 and posted on Feb 4, 2014.
- Applicants must submit their applications by Dec 14, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Independent school districts Public and State controlled institutions of higher education Small businesses Private institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities State governments Special district governments For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR 14-086, titled "Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01)," supports revision applications to existing, active NIH U01 cooperative agreement awards. Rather than funding entirely new stand-alone projects, this FOA is designed for investigators who already hold an NIH U01 and want to expand the scope of that currently funded project by adding one or more new specific aims. In practical terms, it is a way to extend an ongoing U01-supported program into additional, closely related research directions that are responsive to this particular scientific theme.
Scientifically, the focus is on metabolic reprogramming as a strategy to strengthen cancer immunotherapy. The FOA emphasizes building a mechanistic understanding of the metabolic processes that enable strong, durable anti-tumor immune responses in living systems (in vivo). It also calls for research that clarifies how the tumor microenvironment shapes immune cell metabolism and, in turn, how that metabolic landscape can limit or derail immune effector functions. The core idea is that tumors and immune cells compete for nutrients and operate under stressful conditions such as low oxygen and altered pH, and these conditions can push immune cells into dysfunctional states. Projects are expected to generate actionable insight into these processes and then use that knowledge to manipulate metabolism in ways that improve immunotherapy outcomes.
A key expectation of the FOA is that revision applications will stimulate collaborative research. The cooperative agreement (U01) structure typically involves substantial scientific interaction with NIH staff compared with more independent grant mechanisms, and the FOA language underscores team-based efforts that link mechanistic biology with translational intent. The revisions should therefore propose new aims that clearly extend the parent U01 project, add meaningful capability or direction, and fit into a broader collaborative plan aimed at understanding and altering metabolic pathways relevant to tumor immunity.
On eligibility, the opportunity is broad and includes many organizational types, such as public and private institutions of higher education, nonprofit and for-profit organizations (including small businesses), and multiple levels of government (state, county, city/township, special districts, and certain housing authorities). It also includes tribal governments and tribal organizations, as well as a wide range of mission-specific institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISI institutions. Importantly, non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy. The central practical eligibility requirement implied by the FOA is that the applicant must be an investigator with an active NIH U01 award, since this is specifically for revisions to an existing U01 cooperative agreement project.
Administratively, this is a discretionary funding opportunity using the cooperative agreement instrument, and it falls under NIH’s health-related research mission with the CFDA number 93.396 (Cancer Biology Research). There is no cost sharing or matching requirement. The FOA was posted on February 4, 2014, with an original and current closing date of December 14, 2016, and an archive date of January 14, 2017, indicating the announcement is no longer active for new submissions under those deadlines. The sponsoring agency is the National Institutes of Health, and the full announcement is available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/pa-files/PAR-14-086.html (spacing and formatting may vary depending on how the link is copied). For access or technical issues related to the announcement, the contact listed is the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, PAR 14-086 is best understood as a targeted add-on funding path for existing NIH U01 projects, intended to accelerate progress in a specific research area: understanding how metabolism governs anti-tumor immunity inside the tumor microenvironment and leveraging that knowledge to reprogram metabolic pathways in tumors and/or immune cells to make cancer immunotherapies work better.
FAQs: NIH PAR-14-086 (U01) Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy
1) What is PAR-14-086?
PAR-14-086 is an NIH funding opportunity announcement (FOA) titled "Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (U01)." It supports revision applications to existing, active NIH U01 cooperative agreement awards, with a scientific focus on metabolic reprogramming to strengthen cancer immunotherapy.
2) Is this FOA for new stand-alone projects or for changes to an existing award?
This FOA is specifically for revisions to an existing, active NIH U01 cooperative agreement project. It is not intended to fund entirely new stand-alone projects.
3) What does "revision application" mean in the context of this opportunity?
In this FOA, a revision application means proposing to expand the scope of a currently funded U01 project by adding one or more new specific aims that extend the parent award in a way that is responsive to the FOA's scientific theme.
4) Who is the intended applicant for PAR-14-086?
The practical eligibility requirement implied by the FOA is that the applicant is an investigator with an existing, active NIH U01 cooperative agreement award who wants to expand that funded project with additional aims aligned to the FOA topic.
5) What is the core scientific theme of this FOA?
The FOA focuses on metabolic reprogramming as a strategy to improve cancer immunotherapy. Projects are expected to build mechanistic understanding of metabolic processes that support strong and durable anti-tumor immune responses in vivo, and to use that knowledge to manipulate metabolism in ways that improve immunotherapy outcomes.
6) What does the FOA emphasize about the type of scientific understanding expected?
The FOA emphasizes mechanistic understanding, particularly in living systems (in vivo). It also calls for clarifying how the tumor microenvironment shapes immune cell metabolism and how that metabolic landscape can limit or derail immune effector functions.
7) What role does the tumor microenvironment play in the research focus described?
The FOA highlights that tumors and immune cells compete for nutrients and function under stressful conditions such as low oxygen and altered pH. These conditions can push immune cells into dysfunctional states, which can weaken anti-tumor immunity and undermine immunotherapy effectiveness.
8) What kinds of outcomes or deliverables are implied for proposed revision aims?
Revision aims are expected to generate actionable insight into tumor-immune metabolic interactions and then leverage that understanding to manipulate metabolic pathways in tumors and/or immune cells to improve immunotherapy outcomes.
9) Does the FOA encourage collaboration, and if so, why?
Yes. A key expectation is that revision applications will stimulate collaborative research. The U01 cooperative agreement structure typically involves substantial scientific interaction with NIH staff, and the FOA underscores team-based efforts linking mechanistic biology with translational intent.
10) What does the U01 cooperative agreement mechanism imply for how the project is conducted?
The U01 is a cooperative agreement instrument, which typically involves substantial scientific interaction with NIH staff compared with more independent grant mechanisms. The FOA language reinforces that the revision should fit within a collaborative plan.
11) How should the new aims relate to the parent U01 project?
The new aims should clearly extend the parent U01 project, add meaningful capability or direction, and remain closely related to the currently funded program while being responsive to the FOA's metabolic reprogramming and tumor immunity theme.
12) What types of organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofit and for-profit organizations (including small businesses); and multiple levels of government (state, county, city/township, special districts, and certain housing authorities). It also includes tribal governments and tribal organizations.
13) Are mission-specific or minority-serving institutions included in eligibility?
Yes. The FOA includes a range of mission-specific institutions such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian-serving institutions, and AANAPISI institutions.
14) Are foreign organizations or non-U.S. entities eligible?
Yes. Non-U.S. entities (foreign organizations and foreign institutions) are eligible to apply. In addition, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy.
15) Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
16) Which NIH mission area and CFDA number are associated with this opportunity?
The opportunity falls under NIH's health-related research mission and lists CFDA number 93.396 (Cancer Biology Research).
17) When was the FOA posted, and what were the key dates?
The FOA was posted on February 4, 2014. The original and current closing date listed is December 14, 2016, and the archive date is January 14, 2017.
18) Is PAR-14-086 still open for submissions?
Based on the listed closing date (December 14, 2016) and archive date (January 14, 2017), this announcement is no longer active for new submissions under those deadlines.
19) Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
20) Where can applicants find the full FOA text?
The full announcement is available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PAR-14-086.html
21) Who should be contacted for access or technical issues with the announcement?
For access or technical issues related to the announcement, the listed contact is the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
22) What is the simplest way to describe the purpose of PAR-14-086?
It is a targeted add-on funding path for existing NIH U01 projects to accelerate progress in understanding how metabolism governs anti-tumor immunity in the tumor microenvironment and how metabolic reprogramming can make cancer immunotherapies work better.
Browse more opportunities from the same category: Education Health
Next opportunity: Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01)
Previous opportunity: Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 086
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 086) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Research on Metabolic Reprogramming to Improve Immunotherapy (P01) Apply for PAR 14 087 Funding Number: PAR 14 087 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 15 005 Funding Number: RFA DA 15 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV Infection of the Central Nervous System (R01) Apply for PA 14 094 Funding Number: PA 14 094 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from Central Nervous System Reservoirs (R01) Apply for PA 14 095 Funding Number: PA 14 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization Apply for RFA CA 14 002 Funding Number: RFA CA 14 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| NIDA Avant Garde Award Program for HIV/AIDS and Drug Use Research (DP1) Apply for RFA DA 15 004 Funding Number: RFA DA 15 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Software and Analysis Methods for Biomedical Big Data in Targeted Areas of High Need (U01) Apply for RFA HG 14 020 Funding Number: RFA HG 14 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R21) Apply for PAR 14 013 Funding Number: PAR 14 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R21) Apply for PA 14 113 Funding Number: PA 14 113 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Family Centered Self Management of Chronic Conditions (R01) Apply for PA 14 112 Funding Number: PA 14 112 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21) Apply for PAR 14 105 Funding Number: PAR 14 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03) Apply for PAR 14 104 Funding Number: PAR 14 104 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01) Apply for PAR 14 106 Funding Number: PAR 14 106 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PAR 14 115 Funding Number: PAR 14 115 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) Apply for PAR 14 116 Funding Number: PAR 14 116 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 086", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.